Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ian Haydock

Tokyo, Japan
Ian is head of pharma news content for the Asia-Pacific area and has been covering the region for more than 20 years as an editor for Scrip and more recently as managing editor of PharmAsia News. He has a long background in Asia, having grown up in Hong Kong, and a particular interest in regional regulatory harmonization and trade initiatives and the development of the Japanese pharma sector. Ian lives in Tokyo with his wife and two sons.
Advertisement
Set Alert for Articles By Ian Haydock

Latest From Ian Haydock

Otsuka Bags Novel Antibody Tech, Pipeline In $430m Visterra Buy

Otsuka liked the private US antibody tech company Visterra so much that it is buying it, in a move developing out of licensing discussions and which the Japanese firm says will strengthen its presence in biologics for renal disorders and other high-need areas.

M & A Biologics

Tasly Gains Products As Transgene Sells Up China JV Stake

Transgene is divesting its Chinese joint venture to local partner Tasly, which is also acquiring selected rights to two Transgene products ahead of a planned IPO, in deal that will see the French firm net close to $50m in stock.
China Commercial

Enfortumab Progresses As US Accelerated Approval Eyed In Urothelial Cancer

Astellas and Seattle Genetics now expect key top-line data on their antibody-drug conjugate in urothelial cancer in the first half of next year, as pivotal trials in support of a planned US accelerated approval progress.
Cancer United States

Finance Watch: Global Ventures Step Into The Spotlight As The US Takes A Breather

Private Company Edition: I-Mab's $220m Series C round continued the trend of big investments in companies focused on or headquartered in China. Also, Shanghai-based Nuance brought in a combined $35m and European firms dominated recent small financings as US VC deals took a summer break.

Financing StartUps and SMEs

BAN2401 Results Validate Eisai/Biogen's Faith In Alzheimer's Amyloid Tack

In the wake of multiple recent drug failures in the Alzheimer's sector, Eisai and partner Biogen announce "impressive" top-line results for an amyloid-targeting antibody that provide important support for the amyloid hypothesis and may also bode well for the companies' lead candidate in the same class.

Clinical Trials Neurology

New Takeda HQ Reflects Strategic Direction Amid Lingering Doubters

The official opening of Takeda's new global headquarters in Tokyo abounds with actual and implied symbolism as CEO Christophe Weber looks to take the company into the global top 10 through the Shire acquisition while maintaining its Japanese roots.

Japan Commercial
See All
Advertisement
UsernamePublicRestriction

Register